These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Midostaurin approved for FLT3-mutated AML. Levis M Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144 [TBL] [Abstract][Full Text] [Related]
26. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792 [TBL] [Abstract][Full Text] [Related]
27. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Smith CC; Wang Q; Chin CS; Salerno S; Damon LE; Levis MJ; Perl AE; Travers KJ; Wang S; Hunt JP; Zarrinkar PP; Schadt EE; Kasarskis A; Kuriyan J; Shah NP Nature; 2012 Apr; 485(7397):260-3. PubMed ID: 22504184 [TBL] [Abstract][Full Text] [Related]
28. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568 [No Abstract] [Full Text] [Related]
29. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Battipaglia G; Ruggeri A; Massoud R; El Cheikh J; Jestin M; Antar A; Ahmed SO; Rasheed W; Shaheen M; Belhocine R; Brissot E; Dulery R; Eder S; Giannotti F; Isnard F; Lapusan S; Rubio MT; Vekhoff A; Aljurf M; Legrand O; Mohty M; Bazarbachi A Cancer; 2017 Aug; 123(15):2867-2874. PubMed ID: 28387928 [TBL] [Abstract][Full Text] [Related]
30. Molecularly targeted therapies for acute myeloid leukemia. Stein EM Hematology Am Soc Hematol Educ Program; 2015; 2015():579-83. PubMed ID: 26637775 [TBL] [Abstract][Full Text] [Related]
31. Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy. Schroeder T; Zohren F; Saure C; Bruns I; Czibere A; Safaian NN; Fenk R; Haas R; Kobbe G Acta Haematol; 2010; 124(3):153-9. PubMed ID: 20938170 [No Abstract] [Full Text] [Related]
32. Midostaurin Gets FDA Nod for AML. Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740 [TBL] [Abstract][Full Text] [Related]
33. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Sato T; Yang X; Knapper S; White P; Smith BD; Galkin S; Small D; Burnett A; Levis M Blood; 2011 Mar; 117(12):3286-93. PubMed ID: 21263155 [TBL] [Abstract][Full Text] [Related]
34. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205 [TBL] [Abstract][Full Text] [Related]
35. FLT3 inhibitors in acute myeloid leukemia: Current and future. Thomas CM; Campbell P J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754 [TBL] [Abstract][Full Text] [Related]
36. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3. Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308 [TBL] [Abstract][Full Text] [Related]
37. Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. Sammons SL; Pratz KW; Smith BD; Karp JE; Emadi A Am J Hematol; 2014 Sep; 89(9):936-8. PubMed ID: 24898801 [No Abstract] [Full Text] [Related]
38. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis. Sly N; Gaspar K Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289 [TBL] [Abstract][Full Text] [Related]
39. Midostaurin for patients with acute myeloid leukemia and FLT3 mutations. Levis MJ Clin Adv Hematol Oncol; 2019 Jun; 17(6):323-325. PubMed ID: 31437132 [No Abstract] [Full Text] [Related]